Search clinical trials for: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab

Total 474 results

Northwestern University
National Cancer Institute (NCI)

Recruiting

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Colorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E Mutation

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Asthma | Healthy Participants

Australia
Jiangsu Simcere Biologics Co., Ltd

Recruiting

A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

Advanced Solid Tumor | Cutaneous T Cell Lymphoma

China
Biogen

Terminated

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin's
Centre Francois Baclesse
GRECAN

Completed

Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors (ABT737 exvivo)

Ovarian Cancer

France
Sheba Medical Center

Unknown

Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus (COSTA)

COVID - 19

Israel
Swiss Group for Clinical Cancer Research

Recruiting

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients (salVage)

Non-small Cell Lung Cancer (NSCLC) | Stage IV

Switzerland
Glycotope GmbH

Completed

Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors (GATTO)

Solid Tumor, Adult

Germany, Italy, Spain
Orthofix s.r.l.

Active, not recruiting

Observational Clinical Study on Elderly Patients With Fracture of the Proximal Femur Treated With the Chimaera Nail (Chimaera)

Hip Fractures | Intertrochanteric Fractures | Pertrochanteric Fracture | Subtrochanteric Fractures

Italy
Shen Lin

Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Colorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2

China
Peking Union Medical College

Not yet recruiting

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Salivary Gland Cancer
Dizal Pharmaceuticals

Active, not recruiting

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Breast Cancer Metastatic

China, United States
Cyteir Therapeutics, Inc.

Active, not recruiting

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Soft Tissue Sarcoma | Follicular Lymphoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Multiple Myeloma | Pancreatic Cancer | Ovarian Cancer | Mantle Cell Lymphoma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | DLBCL | Non-hodgkin Lymphoma | Malignancy | CLL

United States
Hospices Civils de Lyon

Unknown

MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (CHLOROTRAMMEL)

Metastatic NRAS Melanoma

France
Institut Paoli-Calmettes
Innate Pharma

Recruiting

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)

Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer | Oesophageal Cancer | Metastatic Ovary Cancer

France
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Not yet recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice (FIL_MAB)

Non-Hodgkin Lymphoma, B-cell

Italy
University of Alabama at Birmingham
Eli Lilly and Company

Completed

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Stage IV Non-Small Cell Lung Cancer

United States
The First People's Hospital of Changzhou

Not yet recruiting

Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC

Colorectal Cancer Metastatic
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Ming Hou
Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaborators

Completed

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
The First Affiliated Hospital of Nanchang University

Active, not recruiting

Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

Helicobacter Pylori Infection

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China
Leiden University Medical Center

Recruiting

Influence of Δ9-tetrahydrocannabinol (THC) on Oxycodone Induced Ventilatory Depression in Healthy Volunteers (COXY)

Cannabis Use | Opioid Use | Respiratory Depression

Netherlands
University of Ulm

Completed

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application (CasiTocCOVID)

COVID-19 | Critically Ill | Outcome, Fatal | Interleukin 6 | Tocilizumab

Germany
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Biogen

Terminated

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin's
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
Treace Medical Concepts, Inc.

Recruiting

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D) (MTA3D)

Hallux Valgus | Metatarsus Adductus

United States
Genelux Corporation

Completed

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

United States
Dayanand Medical College and Hospital

Completed

Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium (GCNI-CHC)

Hepatitis, Chronic

India
University of Texas Southwestern Medical Center

Active, not recruiting

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (DARTBOARD)

Head and Neck Cancer

United States
Mandana Kamgar, MD

Recruiting

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Pancreatic Ductal Adenocarcinoma

United States
Qilu Hospital of Shandong University

Recruiting

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Colon Cancer

China
Hip Innovation Technology

Recruiting

Safety and Effectiveness of the HIT Reverse HRS

Osteoarthritis, Hip | Avascular Necrosis of Hip | Degenerative Joint Disease | Traumatic Arthropathy-Hip

United States
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Active, not recruiting

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

Colorectal Cancer Metastatic

Ireland, France, Israel
InventisBio Co., Ltd
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Solid Tumors

NSCLC | Solid Tumor, Adult | CRC

United States, Taiwan, Australia, Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
BioNumerik Pharmaceuticals, Inc.
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of...

Completed

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Non-small Cell Lung Cancer

Poland, Russian Federation, Bulgaria, United States, Romania, Ukraine
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
Assistance Publique - Hôpitaux de Paris
GlaxoSmithKline

Recruiting

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia (RITUX-PLUS 2)

Primary Immune Thrombocytopenia (ITP)

France
University of Kansas Medical Center
Penumbra Inc.

Completed

Safety and Efficacy of Thrombolysis in Combination With Endhole Aspiration in the Treatment of Acute DVT (INDIGO)

Acute Deep Vein Thrombosis

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
The European Research Group on Periodontology (ERGOPerio)
The University of Hong Kong

Completed

Mechanisms of LPRF Action in the Promotion of Wound Healing and Tissue Regeneration

Gingival Recession

Hong Kong
University of Bologna
Compagnia di San Paolo

Completed

Treatment of Depression in Acute Coronary Syndrome (ACS) Patients (TREATED-ACS)

Depression

Italy
Raymond T. Chung, MD
Merck Sharp & Dohme LLC

Withdrawn

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Hepatitis C | Cardiac Transplant Disorder

United States
Uppsala University

Completed

Factors Associated With Decisions to Withhold or Withdraw Intensive Care

COVID-19 | Sepsis | ARDS, Human

Sweden
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine

Search clinical trials for: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations